Healthcare
Amgen Inc.(AMGN)
Live Price
Offline$337.60
-1.19% today
1Y Change
+20.42%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $174.78B
- Revenue Growth
- +9.9%
- EPS Growth
- +88.1%
- Dividend Yield
- 3.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Amgen Inc. (AMGN) is a Healthcare stock with a market cap of $174.78B and listed on NASDAQ. The stock last traded around $337.60 and up 20.4% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +9.9%, EPS growth of +88.1%, a dividend yield of 3.0%. What stands out right now is revenue +9.9%, EPS +88.1%, free cash flow -22.1% with operating margin 31.6% and ROIC 13.9%. The dividend matters to the case here, with a current yield around 3.0%. Valuation sits in the middle of the pack at P/E 22.4 and price/sales 4.7. Stock Foundry combines AMGN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+9.9% vs +7.6% peer median
Operating Margin
Above sector median
+31.6% vs +19.4% peer median
P/E
Below sector median
22.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +9.9% and EPS at +88.1%, with operating margin around 31.6%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 3.0%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +8.0% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +0.8% | +2.2% | +6.2% |
2026 Feb 3, 2026 | +11.8% | +8.2% | +7.7% | +12.0% |
2025 Nov 4, 2025 | +12.3% | +7.8% | +14.1% | +16.4% |
Benchmark Edge
AMGN vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
AMGN
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
AMGN Max Drawdown
-16.57%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for AMGN and SPY.
Company Overview
Amgen Inc.
NASDAQ Global Select
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behรงet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
- Leadership
- Robert A. Bradway
- IPO Date
- Jun 17, 1983
- Employees
- 28.0k
- Street Address
- One Amgen Center Drive
- Mailing
- Thousand Oaks, CA, 91320-1799
- Region
- Thousand Oaks, CA, US
- Reporting Currency
- USD
- Investor Line
- 805 447 1000
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 22.4
- EV/EBITDA
- 12.7
- Price/Sales
- 4.7
- Price/Book
- 19.0
Growth
- Revenue
- +9.9%
- EPS
- +88.1%
- Free Cash Flow
- -22.1%
Profitability
- Gross Margin
- 71.5%
- Operating Margin
- 31.6%
- Net Margin
- 20.9%
- ROE
- 89.4%
- ROIC
- 13.9%
Balance Sheet
- Debt/Equity
- 6.24
- Current Ratio
- 1.26
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.